Search filters

Filters
Clear All

Phase

  • 182
  • 151
  • 2
  • 188
  • 147
  • 17
  • 373
  • 1196
  • 568
  • 28
  • 44
  • 2
  • 1128
  • 1197
  • 5

Found 1202 All Conditions trials

A listing of All Conditions medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

 2D AND 4D CONTRAST-ENHANCED ULTRASOUND EVALUATION OF HEPATOCELLULAR CARCINOMA CHEMOEMBOLIZATION
99 years or below
All genders
This is an open-label, non-randomized trial that will be conducted at three clinical sites. The subject population will be patients undergoing transarterial chemoembolization (TACE) for the treatment of hepatocellular carcinoma (HCC) at Thomas Jefferson University, The University of California, San Diego, and University of Pennsylvania. Patients will receive a contrast-enhanced …
 RADVAX FOR RELAPSED/REFRACTORY HODGKIN LYMPHOMA: A PHASE II TRIAL OF NIVOLUMAB + LOW DOSE RADIOTHERAPY FOR INCOMPLETE RESPONDERS
99 years or below
All genders
Phase 2
This is a Phase II single-arm, single-site, open label clinical trial with r/r HL patients, aimed to determine whether a RadVax approach using low-dose RT added to nivolumab can improve response among patients who do not achieve a CR to nivolumab alone. The long-term goal is to develop an effective …
 EVALUATION OF THE VALIANT MONA LSA THORACIC STENT GRAFT SYSTEM IN DESCENDING THORACIC AORTIC ANEURYSMS AND CHRONIC DISSECTIONS
99 years or below
All genders
The trial involves an investigational device (not approved by the FDA) for subjects who have an aneurysm (bulge), dissection (tear) or a penetrating ulcer (bubble) of the descending aorta that involve an artery (main blood vessel in your body). The subject must need to have one of their blood vessels …
 Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)  A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers
99 years or below
All genders
Phase 3
The purpose of this study is to find if adding the study drug, nivolumab (also known as OPVIDO), will limit lung cancer from growing back in patients with early stage non-small cell lung cancer. Nivolumab is a drug that may turn on the body's immune system to attack any cancer …
 UPCC 04717: Phase I  open label  dose-escalation study to evaluate the safety  expansion  persistence of a single dose of UCART19 (allogeneic engineered T-cells expressing anti-CD19 chimeric antigen receptor)  administered intravenously in patients with relapsed or refractory CD19 positive B-cell acute lymphoblastic leukaemia (B-ALL)
99 years or below
All genders
Phase 1
The main aims of this study are to test the safety of up to 4 different doses of UCART19, and to identify the best dose of UCART19, by measuring what has happened to the leukemia cells at day 28 (28 days after the administration of UCART19), day 84 (84 days …
 UPCC 16517: A Phase 1  First-in-Human  Open-Label  Dose Escalation Study of JNJ-61186372  a Human Bispecific EGFR and cMet Antibody  in Subjects with Advanced Non-Small Cell Lung Cancer
99 years or below
All genders
Phase 1
The purpose of this study is to see if JNJ-61186372 is safe and useful for treating patients with advanced, metastatic, non-small cell lung cancer (NSCLC).
 UPCC 06717 / AMC 101: A Pilot Study of Ibrutinib and R-da-EPOCH for Front Line Treatment of AIDS-Related Lymphomas
18 years - 64 years
All genders
Phase 1
Non-Hodgkin lymphoma  is a potentially curable condition with standard cancer treatment drugs (chemotherapy) and steroids. Standard lymphoma treatment includes chemotherapy, or cancer-fighting drugs, called etoposide, vincristine, cyclophosphamide, prednisone and doxorubicin (called EPOCH).  
711 - 720 of 1202